Emergent BioSolutionsの空売り状況は、投資家がEmergent BioSolutionsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Emergent BioSolutions (NYSE:EBS) 株価情報, 空売り情報

Emergent BioSolutions

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Inc

EMPIRE BANCSHARES INC by Empire Bancshares Inc.

Empire Bancshares Inc

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 1% on Thursday.
The Dow traded up 0.01% to 43,731.14 while the NASDAQ rose 1.19% to 19,208.62. The S&amp;P 500 also rose, gaining, 0.55% to 5,961.80.
Check This Out: <a href="https://www.benzinga.com/news/24/11/41801967/top-3-energy-stocks-that-are-ticking-portfolio-bombs">Top 3 Energy Stocks That Are Ticking Portfolio Bombs</a>
Leading and Lagging Sectors Consumer discretionary shares surged by 1.5% on Thursday.
In trading on Thursday, financials shares fell by 1.3%.
Top Headline
Halliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) reported worse-than-expected third-quarter EPS and sales.
HAL reported a third-quarter revenue decline of 1.8% year-over-year to $5.697 billion, missing the consensus of $5.828 billion. Adjusted EPS was 73 cents, down from 79 cents a year ago and below the consensus of 75 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares shot up 43% to $241.02 after the company reported better-than-expected quarterly financial results.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) got a boost, surging 32% to $12.13 after the company announced it evaluated the safety and efficacy of its new clinical trial of Brincidofovir in treating Mpox across Africa. PANTHER will conduct a clinical trial under The Leadership of Africa Centres for Disease Control and Prevention.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares were also up, gaining 36% to $47.35 following third-quarter earnings.</li>
</ul>
Equities Trading DOWN
<ul>
<li>DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares dropped 25% to $17.98 after the company lowered its FY24 guidance and Leerink Partners downgraded the stock from Outperform to Market Perform.</li>
<li>Shares of Digital Turbine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) were down 45% to $1.7694 after the company reported worse-than-expected second-quarter financial results.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) was down, falling 24% to $5.30 after the company reported worse-than-expected third-quarter financial results.</li>
</ul>
Commodities In commodity news, oil traded down 0.3% to $71.46 while gold traded up 1.1% at $2,705.10.
Silver traded up 1.9% to $31.930 on Thursday, while copper rose 4.1% to $4.4185.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.94%, Germany's DAX gained 2.07% and France's CAC 40 rose 1.07%. Spain's IBEX 35 Index rose 1.01%, while London's FTSE 100 rose 0.04%.
The Bank of England cut its Bank Rate by 25bps to 4.75% at its recent meeting. Retail sales in the Eurozone rose 0.5% month-over-month in September versus a revised 1.1% gain in August. The HCOB Eurozone construction PMI climbed to 43.0 in October from 42.1 in the previous month.
The S&amp;P Global France construction PMI climbed to 42.2 in October from 37.9 in the prior month, while German construction PMI declined to 40.2 in October from 41.7 in the previous month.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei 225 falling 0.25%, Hong Kong's Hang Seng Index gaining 2.02%, China's Shanghai Composite Index gaining 2.57% and India's BSE Sensex falling 1.04%.
China&#8217;s trade surplus widened to $95.27 billion in October from $56.13 billion in the year-ago period. Foreign exchange reserves in Singapore increased to SGD 507.6 billion in October from SGD 499.7 billion in the prior month.
Economics
<ul>
<li>U.S. initial jobless claims rose by 3,000 from the previous week to 221,000 in the final week of October, in-line with market expectations.</li>
<li>U.S. nonfarm business sector labor productivity increased by 2.2% in the third quarter compared to a revised 2.1% gain in the prior three-month period.</li>
<li>Unit labor costs in the nonfarm business sector rose an annualized 1.9% during the third quarter compared to a revised 2.4% increase in the earlier period.</li>
<li>U.S. wholesale inventories fell by 0.2% month-over-month to $903.7 billion in September versus the preliminary reading of a 0.1% decline and compared to a 0.2% gain in the prior month.</li>
<li>U.S. natural-gas stocks rose by 69 billion cubic feet to 3.932 trillion cubic feet in the week ended Nov. 1.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41805406/wall-streets-most-accurate-analysts-spotlight-on-3-industrials-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Industrials Stocks With Over 5% Dividend Yields</a></li>
</ul>

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

APPS

BROS

COMM

XRAY

Gold Gains 1%; Halliburton Posts Weak Q3 Results

<h3>Gainers</h3>
<ul>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares moved upwards by 36.8% to $1.98 during Thursday's regular session. The market value of their outstanding shares is at $43.6 million. As per the news, the Q2 earnings report came out today. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares moved upwards by 31.25% to $0.95. The market value of their outstanding shares is at $109.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares increased by 30.76% to $12.03. The market value of their outstanding shares is at $630.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 29.17% to $0.71. The market value of their outstanding shares is at $10.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 23.03% to $0.08. The market value of their outstanding shares is at $4.0 million. </li>
<li>Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) shares rose 19.61% to $5.0. The company's market cap stands at $151.1 million. As per the press release, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares fell 28.7% to $0.92 during Thursday's regular session. The company's market cap stands at $40.4 million. </li>
<li>Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares fell 24.69% to $18.06. The company's market cap stands at $3.6 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) shares declined by 19.54% to $4.49. The market value of their outstanding shares is at $296.0 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) shares decreased by 17.75% to $12.61. The company's market cap stands at $552.6 million. The company's, Q3 earnings came out today. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares fell 17.56% to $2.33. The market value of their outstanding shares is at $101.3 million. As per the press release, Q3 earnings came out today. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares decreased by 16.41% to $3.64. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AXGN

CELU

CHRS

CLOV

ENSC

HBIO

PSNL

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks were higher, with the Nasdaq Composite gaining around 200 points on Thursday.
Shares of HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) rose sharply during Thursday's session after the company reported better-than-expected third-quarter financial results and issued FY24 <a href="https://www.benzinga.com/news/earnings/24/11/41790530/hubspot-shares-climb-after-strong-q3-results-eps-beat-revenues-beat">guidance above estimates</a>.
HubSpot reported quarterly earnings of $2.22 per share, which beat the analyst consensus estimate of $1.91. Quarterly revenue clocked in at $669.7 million which beat the analyst consensus estimate of $646.9 million and is an increase over sales of $557.55 million from the same period last year.
HubSpot shares jumped 7.9% to $645.11 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares jumped 47% to $247.63 after the company reported better-than-expected third-quarter financial results.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) surged 39% to $48.57 following third-quarter earnings.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) gained 34.8% to $12.40 after the company announced it evaluated the safety and efficacy of its new clinical trial of Brincidofovir in treating Mpox across Africa. PANTHER will conduct a clinical trial under The Leadership of Africa Centres for Disease Control and Prevention.</li>
<li>FARO Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) gained 32.8% to $25.07 following third-quarter results.</li>
<li>Under Armour, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) gained 32.7% to $11.61 after the company reported better-than-expected quarterly EPS and sales.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) gained 28.2% to $18.46 after the company reported better-than-expected quarterly financial results.</li>
<li>Freshworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) jumped 26.2% to $16.51 following upbeat quarterly results.</li>
<li>Wolverine World Wide, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) jumped 26.2% to $20.25 following strong quarterly results.</li>
<li>Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) gained 22.4% to $68.66 after the company reported better-than-expected quarterly financial results.</li>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) rose 21.4% to $19.98 following third-quarter results.</li>
<li>Clearwater Analytics Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) gained 20.9% to $34.56 following better-than-expected quarterly earnings.</li>
<li>Hanesbrands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) gained 17% to $8.32 following upbeat earnings.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) rose 16% to $120.80 following stronger-than-expected quarterly earnings.</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) gained 15.5% to $29.20 after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance above estimates.</li>
<li>Kyndryl Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) gained 15.3% to $27.81 after reporting upbeat quarterly results.</li>
<li>Warner Bros. Discovery, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NYSE">WBD</a>) surged 14.7% to $9.61 following third-quarter earnings.</li>
<li>EPAM Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) gained 13.7% to $230.60 after the company reported better-than-expected third-quarter financial results and issued FY24 guidance above estimates.</li>
<li>McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) rose 10.4% to $606.61 as the company reported better-than-expected second-quarter financial results.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) gained 9.7% to $16.95.</li>
<li>The Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) gained 6.6% to $67.46.</li>
<li>Arm Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NYSE">ARM</a>) gained 5.4% to $152.43 following second-quarter results.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41806634/jim-cramer-recommends-buying-this-utilities-stock-says-no-to-xp"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41806634/jim-cramer-recommends-buying-this-utilities-stock-says-no-to-xp">Jim Cramer Recommends Buying This Utilities Stock, Says No To XP</a></li>
</ul>

Intraday Update

CWAN

EPAM

FARO

FRSH

HUBS

IONQ

LYFT

MBLY

HubSpot Posts Better-Than-Expected Results, Joins Under Armour, Lyft, Wolverine World Wide, Zillow And Other Big Stocks Moving Higher On Thursday

Benchmark analyst Robert Wasserman maintains Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) with a Buy and raises the price target from $8 to $12.

Price Target

Analyst Ratings

Benchmark Maintains Buy on Emergent BioSolutions, Raises Price Target to $12

WIIM

Emergent BioSolutions shares are trading higher after the company announced it evaluated the safety and efficacy of its new clinical trial of Brincidofovir in treating Mpox across Africa. PANTHER will conduct a clinical trial under The Leadership of Africa Centres for Disease Control and Prevention

<h3 class="wp-block-heading">The Day After</h3>
I wrote a post on ZeroHedge this morning ("<a href="https://www.zerohedge.com/news/2024-11-06/victory">Trump Victory</a>") which included a number of reactions to Trump's astonishing victory last night. Trump became the first President to win in non-consecutive terms since Grover Cleveland, 127 years ago. Here, I'll confine myself to some market-related comments.
<h3 class="wp-block-heading">The Betting Markets</h3>
In&nbsp;<a href="https://portfolioarmor.substack.com/p/betting-on-the-election">a post</a>&nbsp;here a couple of weeks ago, I wrote about betting on the election.
<figure class="wp-block-image aligncenter size-full is-resized"><a href="https://portfolioarmor.substack.com/p/betting-on-the-election"><img loading="lazy" decoding="async" width="917" height="626" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07084434/Betting-On-The-Election--1.jpg" alt="" class="wp-image-3043" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07084434/Betting-On-The-Election--1.jpg 917w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07084434/Betting-On-The-Election--1-300x205.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07084434/Betting-On-The-Election--1-768x524.jpg 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
I mentioned that I had Trump to win at 44 cents on PredictIt, and a couple of bets on a new site,&nbsp;<a href="http://kalshi.com/sign-up/?referral=0297c7e8-2fe6-4b35-8f98-0366b8795934">Kalshi</a>:
<ol>
<li>Trump to win Wisconsin at 52%.</li>
<li>Republicans to win the White House, House, and Senate at 47%.</li>
</ol>
After that post, I added a few additional bets. One was "Kamala No" on PredictIt, when that dropped to 48 cents. I cashed out of my PredictIt bets at 97 cents and 98 cents, respectively, for gains of a little over 100% before PredictIt's 5% exit fee.
Trump won Wisconsin; all the House races haven't settled yet, but it looks like our Republican sweep bet will cash too.
<h3 class="wp-block-heading">Stocks Benefiting From The Trump Win</h3>
Six names we have positions in posted double-digit gains the day after Trump's win:
 Centrus Energy Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>). This is a uranium name we opened a call spread on last week.&nbsp;
<figure class="wp-block-image size-full is-resized"><a href="https://portfolioarmor.substack.com/p/trade-alert-the-nuclear-option"><img loading="lazy" decoding="async" width="882" height="606" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07084722/The-Nuclear-Option.jpg" alt="" class="wp-image-3044" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07084722/The-Nuclear-Option.jpg 882w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07084722/The-Nuclear-Option-300x206.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07084722/The-Nuclear-Option-768x528.jpg 768w" sizes="(max-width: 882px) 100vw, 882px" /></a></figure>
Robinhood Markets, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>). That was the crypto-related name in our Nuclear Option post above, and our trade was buying the $32 strike calls on it for $2.30. Those calls were trading at $4.90 as of Wednesday's close. 
Bit Digital, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>). That's the Bitcoin miner with operations in Ethereum staking and AI that was one of our two lottery tickets in this post in September.&nbsp;<a href="https://portfolioarmor.substack.com/p/trade-alert-two-lottery-tickets"></a>
Tesla, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>). We opened another trade on Tesla earlier this week. That was the less-contrarian trade in this post. Our Tesla trade is a call spread which will generate a 300% gain if Tesla closes above $350 per share at the end of next year.&nbsp;
<figure class="wp-block-image size-full is-resized"><a href="https://portfolioarmor.substack.com/p/trade-alert-ai-da2"><img loading="lazy" decoding="async" width="886" height="597" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085048/Trade-Alert-AI.jpg" alt="" class="wp-image-3045" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085048/Trade-Alert-AI.jpg 886w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085048/Trade-Alert-AI-300x202.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085048/Trade-Alert-AI-768x517.jpg 768w" sizes="(max-width: 886px) 100vw, 886px" /></a></figure>
Emergent BioSolutions, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>). Our trade here was buying the $9 strike calls expiring on December 20th for $2.05. EBS beat earnings on Wednesday and was up 24.46% after hours.&nbsp;
<figure class="wp-block-image size-full is-resized"><a href="https://portfolioarmor.substack.com/p/trade-alert-biotech"><img loading="lazy" decoding="async" width="888" height="596" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085412/Biotech.jpg" alt="" class="wp-image-3046" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085412/Biotech.jpg 888w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085412/Biotech-300x201.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085412/Biotech-768x515.jpg 768w" sizes="(max-width: 888px) 100vw, 888px" /></a></figure>
Powell Industries, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>). Our most recent trade here was a call spread betting on POWL being above $300 by next May. It closed at $347 today.&nbsp;
<figure class="wp-block-image size-full is-resized"><a href="https://portfolioarmor.substack.com/p/trade-alert-top-names-879"><img loading="lazy" decoding="async" width="885" height="595" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085455/POWL.jpg" alt="" class="wp-image-3047" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085455/POWL.jpg 885w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085455/POWL-300x202.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085455/POWL-768x516.jpg 768w" sizes="(max-width: 885px) 100vw, 885px" /></a></figure>
<h2 class="wp-block-heading">Stocks That Tumbled The Day After</h2>
<ol>
<li>Super Micro Computer, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>). That was the contrarian trade mentioned in the same post with Tesla above. Our bet was that most of the bad news was in the rearview. So there was a good chance the stock would bounce after earnings on Tuesday. Unfortunately, they didn't offer any timeline about getting a new auditor and the stock plummeted on Wednesday.</li>
<li>Rivian Automotive, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>). This EV maker was in a number of analysts "Harris basket" of stocks. Meanwhile, they had Tesla in their Trump baskets, and it plummeted about 9% after Trump won. We opened a position in this one back in April, buying the $15 strike calls expiring in January for $1.84. Fortunately, we sold half of those calls at $5.55 in July, for a 202% gain. So we are playing with the house's money on this one. And the company reports earnings after the close on Thursday. Maybe they'll have some good news then. </li>
</ol>
<figure class="wp-block-image size-full is-resized"><a href="https://portfolioarmor.substack.com/p/trade-alert-evs"><img loading="lazy" decoding="async" width="877" height="590" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085820/EVs.jpg" alt="" class="wp-image-3048" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085820/EVs.jpg 877w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085820/EVs-300x202.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07085820/EVs-768x517.jpg 768w" sizes="(max-width: 877px) 100vw, 877px" /></a></figure>
<h3 class="wp-block-heading">If You Are Concerned About Downside Risk</h3>
If you would like a heads up next time we place a trade, you can subscribe to our trading Substack/occasional email list below.
<figure class="wp-block-image size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="602" height="418" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07090037/Widget.jpg" alt="" class="wp-image-3049" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07090037/Widget.jpg 602w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/07090037/Widget-300x208.jpg 300w" sizes="(max-width: 602px) 100vw, 602px" /></a></figure>

Government

Market Summary

General

BTBT

HOOD

POWL

RIVN

SMCI

TSLA

The Post-Trump Victory Trade

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares rose 31.7% to $0.72 during Thursday's pre-market session. The company's market cap stands at $10.8 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock increased by 24.03% to $1.6. The market value of their outstanding shares is at $24.5 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares increased by 22.93% to $11.31. The company's market cap stands at $592.6 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock rose 20.4% to $0.12. The company's market cap stands at $1.3 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock increased by 18.14% to $0.26. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock rose 17.25% to $0.49. The company's market cap stands at $4.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) shares decreased by 15.5% to $3.5 during Thursday's pre-market session. The company's market cap stands at $286.8 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares decreased by 14.69% to $1.22. The market value of their outstanding shares is at $7.1 million. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) stock decreased by 9.89% to $3.92. The market value of their outstanding shares is at $1.9 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) shares fell 9.51% to $2.0. The market value of their outstanding shares is at $392.4 million. As per the news, the Q3 earnings report came out today. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) stock fell 9.14% to $5.07. The company's market cap stands at $334.2 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock decreased by 8.78% to $2.6. The market value of their outstanding shares is at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CPHI

ESPR

LGMK

PSTV

SNES

STRO

SYRA

VSEE

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock rose 31.7% to $0.72 during Thursday's pre-market session. The market value of their outstanding shares is at $10.8 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) shares rose 24.03% to $1.6. The company's market cap stands at $24.5 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares rose 22.93% to $11.31. The market value of their outstanding shares is at $592.6 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares rose 20.4% to $0.12. The market value of their outstanding shares is at $1.3 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares moved upwards by 18.14% to $0.26. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares increased by 17.25% to $0.49. The company's market cap stands at $4.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) stock fell 15.5% to $3.5 during Thursday's pre-market session. The market value of their outstanding shares is at $286.8 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock declined by 14.69% to $1.22. The company's market cap stands at $7.1 million. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares declined by 9.89% to $3.92. The company's market cap stands at $1.9 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) shares declined by 9.51% to $2.0. The company's market cap stands at $392.4 million. As per the news, the Q3 earnings report came out today. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) stock fell 9.14% to $5.07. The company's market cap stands at $334.2 million. The company's, Q3 earnings came out yesterday. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares fell 8.78% to $2.6. The company's market cap stands at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Shares of Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41789162/lyft-stock-drives-higher-after-better-than-expected-q3-results">better-than-expected quarterly results.</a>
Lyft reported quarterly losses of three cents per share which beat the analyst consensus estimate for losses of four cents. Quarterly revenue came in at $1.52 billion which beat the analyst consensus estimate of $1.44 billion and is an increase over sales of $1.15 billion from the same period last year.
Lyft shares rose 21.5% to $17.49 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>AtlasClear Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NYSE">ATCH</a>) gained 89.6% to $0.3412 in pre-market trading after gaining around 13% on Wednesday.</li>
<li>Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) rose 81.5% to $0.1650 in pre-market trading. Interactive Strength will release third quarter results before the market opens on Thursday, Nov. 14.</li>
<li>MDJM Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDJH#NASDAQ">MDJH</a>) shares surged 49.7% to $0.2252 in pre-market trading after declining around 6% on Wednesday.</li>
<li>Ensysce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) gained 32.6% to $0.7305 in pre-market trading after gaining 5% on Wednesday.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) climbed 27.5% to $214.84 in pre-market trading after the company reported better-than-expected third-quarter financial results.</li>
<li>Laird Superfood, Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSF#NYSE">LSF</a>) shares rose 22% to $8.99 in pre-market trading after the company reported better-than-expected third-quarter financial results.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) gained 19.8% to $11.03 in pre-market trading after posting strong quarterly earnings.</li>
<li>Freshworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) gained 17.7% to $15.40 in pre-market trading following better-than-expected quarterly earnings.</li>
<li>The Oncology Institute, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) gained 17.6% to $0.3469 in pre-market trading. The Oncology Institute will release its third quarter financial results after the market close on Wednesday, Nov. 13.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) gained 15.8% to $40.49 in pre-market trading following strong quarterly results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Digital Turbine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) shares tumbled 41.1% to $1.91 in pre-market trading after reporting downbeat quarterly results.</li>
<li>FOXO Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NASDAQ">FOXO</a>) shares fell 32% to $0.5321 in pre-market trading after surging 475% on Wednesday.</li>
<li>Cardlytics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) dipped 31.9% to $3.55 in pre-market trading following third-quarter results.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares fell 24.5% to $10.35 in pre-market trading after the company reported third-quarter financial results.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) declined 19% to $11.89 in pre-market trading following third-quarter results.</li>
<li>Burford Capital Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUR#NYSE">BUR</a>) shares dipped 16.4% to $12.21 in pre-market trading. Burford Capital will release its financial results for the three and nine months ended Sept. 30, on Thursday, Nov. 7.</li>
<li>ARB IOT Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) fell 15.4% to $0.6879 in pre-market trading after surging 44% on Wednesday.</li>
<li>Corsair Gaming Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSR#NASDAQ">CRSR</a>) fell 14.1% to $6.12 in today's pre-market trading after the company reported worse-than-expected financial results.</li>
<li>Match Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) fell 12.8% to $33.00 in pre-market trading following mixed third-quarter financial results.</li>
<li>Sutro Biopharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) fell 11.6% to $3.66 in pre-market trading after gaining around 8% on Wednesday.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Pre-Market Outlook

ARBB

ATCH

CDLX

CRSR

FOXO

MDJH

MTCH

SEDG

TRNR

WOLF

Why Lyft Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket

Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) reported quarterly earnings of $1.37 per share which beat the analyst consensus estimate of $0.14 by 878.57 percent. This is a 225.69 percent increase over losses of $(1.09) per share from the same period last year. The company reported quarterly sales of $293.800 million which missed the analyst consensus estimate of $297.500 million by 1.24 percent. This is a 8.61 percent increase over sales of $270.500 million the same period last year.

Earnings Beats

Earnings Misses

Emergent BioSolutions Q3 2024 Adj. EPS $1.37 Beats $0.14 Estimate, Sales $293.800M Miss $297.500M Estimate

<ul>
<li>PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention &nbsp;</li>
</ul>
GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) today announced that brincidofovir (brand name TEMBEXA&#xAE;) will be included in a clinical trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for Disease Control and Prevention (Africa CDC), as part of the ‘MpOx Study in Africa' (MOSA). The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus in a randomized double-blind placebo-controlled trial.

Biotech

Global

Emergent BioSolutions Supports New Clinical Trial Evaluating The Safety And Efficacy Of Brincidofovir In Treating Mpox Virus Across Africa; PANTHER To Conduct Clinical Trial Under The Leadership Of Africa Centres For Disease Control And Prevention

Emergent Biosolutions shares are trading higher after the company announced better-than-expected Q3 EPS despite missing revenue estimates.

Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) raises FY2024 sales outlook from $1.05 billion-1.13 billion to $1.06 billion-1.13 billion.

Guidance

Emergent BioSolutions Raises FY2024 Sales Guidance from $1.05B-1.13B to $1.06B-1.13B

AEMD

APDN

BWVI

CMRX

GOVX

MRNA

TNXP

VRAX

WHO Expands Emergency Use List For Mpox Diagnostics, Adds Cepheid's Xpert Mpox PCR Test And Roche's Cobas MPXV Assay As PCR-Based Gold Standard Options

<a href="https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms">https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms</a>
An infection with the new mpox variant clade 1b has been detected in Germany for the first time, the Robert Koch Institute health authority said on Tuesday. &nbsp;

Reported Earlier, 'New Mpox Variant Detected In Germany: Health Authority' - The Economic Times

Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock is trading higher on Wednesday after the company announced the closing of a $100 million asset-backed<a href="https://www.benzinga.com//node/41138475"> revolving loan facility.</a>
The Details: The new credit facility is aimed at enhancing Emergent&#8217;s liquidity and providing additional financial flexibility to support its operational and strategic initiatives.
At at the end of September, Emergent had a cash balance of about $150 million. Through the new loan facility, Emergent now also has access to up to $100 million in financing.
&#8220;We are pleased to have successfully closed on our new ABL credit facility with favorable terms and an extended maturity, which is further evidence of Emergent&#8217;s strengthened balance sheet and financial position,&#8221; said Joe Papa, president and CEO of Emergent.
How To Buy Emergent BioSolutions Stock
By now you're likely curious about how to participate in the market for Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
See Also: <a href="https://www.benzinga.com/trading-ideas/technicals/24/10/41116889/tesla-stock-speeds-ahead-of-mag7-peers-can-octobers-robotaxi-reveal-keep-the-momentum">Tesla Stock Speeds Ahead Of Mag7 Peers, Can October&#8217;s Robotaxi Reveal Keep The Momentum?</a>
EBS Price Action: At the time of writing, Emergent BioSolutions stock is trading 6.49% higher at $9.02, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: 3196481 from Pixabay.

What's Going On With Emergent BioSolutions Stock Wednesday?

Emergent BioSolutions shares are trading higher after the company announced the closing of a $100 million asset-backed loan facility.

Emergent Biosolutions Announced The Closing Of Credit Agreement Worth $100M Entered On September 30, 2024 Providing For An Asset-based Revolving Loan Facility

Emergent BioSolutions shares are trading higher after CA Gov. Gavin Newsom signed a bill pushing for Narcan in workplace first aid kits.

<a href="https://www.latimes.com/california/story/2024-09-28/california-naloxone-first-aid-kits">https://www.latimes.com/california/story/2024-09-28/california-naloxone-first-aid-kits</a>
Workplaces in California could eventually be required to stock their first aid kits with naloxone or another medication that can stop an opioid overdose under <a href="https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202320240AB1976">a bill</a> signed this week by Gov. Gavin Newsom.
Naloxone, commonly sold under the brand name Narcan, can prevent someone from dying of an opioid overdose if administered promptly by a bystander. The medicine binds to the same receptors in the brain as opioids such as fentanyl, which allows the medicine to displace the opioids and reverse their effects.
Assembly Bill 1976 requires California regulators to craft rules requiring first aid kits in workplaces to contain naloxone or any similar medication approved by the Food &amp; Drug Administration. Such a proposal would have to go before a state board for possible adoption by Dec. 1, 2028.
The bill was <a href="https://www.latimes.com/california/story/2024-01-31/to-prevent-opioid-overdoses-california-bill-would-require-naloxone-in-workplace-first-aid-kits">proposed by Assemblymember Matt Haney</a> (D-San Francisco) and supported by the California Emergency Nurses Assn. and a long list of law enforcement groups. Haney argued that it would dramatically increase the accessibility of naloxone, enabling more lives to be saved.
"If fentanyl continues to be more accessible than naloxone, we're going to keep seeing an increase in overdose deaths in our communities," he said in a statement.
Earlier this summer, AB 1976 was opposed by the National Electrical Contractors Assn. and other groups tied to the construction industry. The groups argued that the decision should be left to the Occupational Safety and Health Standards Board, which could decide whether a mandate made sense for all employers. For instance, they raised concerns about storing Narcan safely at construction sites that are not temperature controlled.
In recent months, however, the bill was amended to only require the Occupational Safety and Health Board to consider such a proposal — not to mandate that such rules be adopted. After that and other changes, NECA and other industry groups dropped their opposition, according to a lobbyist for its California chapter.
The state board focused on occupational safety has already been weighing the idea: Earlier this year, it reviewed a petition from the National Safety Council, a group that aims to eliminate leading causes of preventable deaths, to require employers to provide naloxone at all work sites.
Cal/OSHA concluded that doing so would lead to a "significant reduction in opioid-related deaths in California," with deadly injuries resulting from overdoses at work having risen between 2018 and 2022 from 23 to 117, according to a <a href="https://www.dir.ca.gov/oshsb/documents/petition-602-adopteddecision.pdf">state report</a>. But staff of the Occupational Safety and Health Board cautioned that mandating naloxone in workplace first aid kits could be "unnecessarily burdensome" for some employers.
The state board <a href="https://www.dir.ca.gov/oshsb/documents/petition-602-adopteddecision.pdf">decided</a> that exceptions could be made for employers who face practical barriers to storing or administering the medication. In June, it asked Cal/OSHA to convene an advisory committee to consider changing the state rules in order to require "ready access by employees to opioid antagonists."
AB 1976 will push that process along, advocates said, by setting a deadline for the board to consider such changes.

Politics

'Newsom Signs Bill Pushing For Narcan In Workplace First Aid Kits' - LA Times

Emergent Biosolutions stock jumps 14% post-market on guidance raise

Emergent BioSolutions (EBS) announced that brincidofovir will be included in a clinical trial conducted and sponsored by Panther, under the leaders...

Emergent BioSolutions announces brincidofovir trial in Africa

Emergent BioSolutions Inc. 2024 Q3 - Results - Earnings Call Presentation

Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript

Emergent Biosolutions ( ($EBS) ) has released its Q3 earnings. Here is a breakdown of the information Emergent Biosolutions presented to its invest...

Emergent BioSolutions Shows Strong Q3 2024 Recovery

Benchmark Co. analyst Robert Wasserman maintained a Buy rating on Emergent Biosolutions (EBS – Research Report) today and set a price target of $12...

Emergent Biosolutions (EBS) Gets a Buy from Benchmark Co.

Emergent BioSolutions (EBS) is up 36.1%, or $3.32 to $12.52. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...

Emergent BioSolutions rises 36.1%

Emergent BioSolutions (EBS) is up 23.7%, or $2.18 to $11.38. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...

Emergent BioSolutions rises 23.7%

Emergent BioSolutions (EBS) is up 31.2%, or $2.87 to $12.07. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...

Emergent BioSolutions rises 31.2%

Get caught up quickly on the top news and calls moving stocks with these

Qualcomm, Moderna report quarterly beats: Morning Buzz

DLTR

DUOL

FIVE

GOEV

NSANF

NSANY

PLTR

QCOM

SRPT

TTWO

USFD

Screenshot 2024-09-18 at 12.30.33 AM

BVNKF

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Legal

Press Releases

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

Health Care

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

Financing

Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBS

Management

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

Emergent BioSolutions Reports Third Quarter 2024 Financial Results

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

Comments

Emergent BioSolutions

空売り

Emergent BioSolutions (NYSE:EBS) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル